Positive Regulatory Domain I-Binding Factor 1

A transcriptional repressor protein that contains an N-terminal PR-SET domain, four C-terminal CYS2-HIS2 ZINC FINGERS, and binds the PRDI element in the INTERFERON-BETA gene. It has methyltransferase activity and mediates gene transcription in tissue-specific innate and adaptive immune lymphocyte T-CELLS, repressing expression of proteins that promote exit of these tissue-specific T-cell populations from non-lymphoid organs.

Also Known As:

Networked: 41 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Li, Ting: 2 articles (05/2022 - 01/2014)
2.	Liang, Li: 2 articles (05/2022 - 01/2014)
3.	Nong, Lin: 2 articles (05/2022 - 01/2014)
4.	Zhao, Jing: 2 articles (07/2016 - 01/2014)
5.	Li, Jun-Min: 2 articles (12/2013 - 07/2007)
6.	Wright, Kenneth L: 2 articles (11/2009 - 02/2007)
7.	Chen, Sai-Juan: 2 articles (07/2007 - 06/2007)
8.	Garcia, José-Francisco: 2 articles (07/2007 - 04/2006)
9.	Liu, Yan-Yan: 2 articles (07/2007 - 06/2007)
10.	Shen, Zhi-Xiang: 2 articles (07/2007 - 06/2007)

Related Diseases

1.	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/01/2021 - "SIGNIFICANCE STATEMENT: Pharmacological inhibition of Ca2+-activated K+ channel KCa3.1 increased IL-10 expression in peripheral Treg cells, together with the upregulation of the transcriptional regulators of IL-10: Krüppel-like factor 4, E4 promoter-binding protein 4, and/or B lymphocyte-induced maturation protein 1. The manipulation of IL-10high-producing Treg cells by the pharmacological inhibition of KCa3.1 may be beneficial in the treatment of chronic inflammatory diseases such as inflammatory bowel disease."
2.	Glioma (Gliomas) 05/01/2013 - "In this study, we showed that PRDM1 protein levels were inversely correlated with the pathological grade of gliomas and were predictive of patient survival in a retrospective analysis. "
3.	B-Cell Lymphoma (Lymphoma, B Cell) 01/01/2011 - "Furthermore, a novel osteoclastogenesis-regulating pathway involving two transcriptional repressors [B cell lymphoma 6 (Bcl6) and B lymphocyte-induced maturation protein 1 (Blimp1)] under RANKL stimulation has been discovered. " 07/01/2016 - "Objective To oberseve the expressions of B cell lymphoma 6 (Bcl-6) and B lymphocyte-induced maturation protein 1 (Blimp-1) in the decidua of patients with unexplained recurrent spontaneous abortion (URSA), and investigate the roles that Bcl-6 and Blimp-1 act in URSA. " 02/01/2016 - "Silencing of the B lymphocyte-induced maturation protein 1 (Blimp-1), a pivotal transcriptional regulator during terminal differentiation of B cells into plasma cells with siRNAs is under investigation as novel therapeutic approach in Primary Effusion Lymphoma (PEL), a HHV-8 related and aggressive B cell Lymphoma currently lacking of an efficacious therapeutic approach. " 03/23/2023 - "Increased expression of B cell lymphoma 6 (BCL6) and suppression of B lymphocyte-induced maturation protein 1 (BLIMP1)/PR domain-containing protein 1 (PRDM1) are crucial pathological deviations in DLBCL. " 01/01/2022 - "The phenotype resembled peripheral T helper (Tph) cells with an extrafollicular chemokine receptor pattern and high T-bet and B lymphocyte-induced maturation protein 1 expression, but low B cell lymphoma 6 expression. "
4.	Neoplasms (Cancer) 04/01/2006 - "PRDM1 protein was expressed in some cases of B-cell neoplasia, i.e. " 11/06/2021 - "PRDM12 is a member of the PRDI-BF1 (positive regulatory domain I-binding factor 1) homologous domain (PRDM)-containing protein family, a subfamily of Kruppel-like zinc finger proteins, controlling key processes in the development of cancer. " 07/01/2020 - "PR [positive regulatory domain I-binding factor 1 (PRDI-BF1) and retinoblastoma protein-interacting zinc finger gene (RIZ1)] domain containing 14 (PRDM14), that regulates pluripotency in primordial germ cell, has reported the overexpression and function of stemness in various malignancies, suggesting it as the possible therapeutic target. " 12/01/2013 - "EZH2 protected GC B cells against activation-induced cytidine deaminase (AID) mutagenesis, facilitated cell cycle progression, and silenced plasma cell determinant and tumor suppressor B-lymphocyte-induced maturation protein 1 (BLIMP1). " 06/01/2007 - "(2) Gene product of PRDM1 DNA binding region was not found in microdissected tumor cells, but an abnormal PRDM1 protein about 70 KD was detected simultaneously in whole tumor tissue. "
5.	Lymphoma (Lymphomas) 12/01/2013 - "[Research progress on B lymphocyte-induced maturation protein 1 and its relationship with the development of lymphoma]." 03/01/2012 - "The aim of this review was to summarize recent knowledge of the structure and function of a transcriptional repressor, B lymphocyte induced maturation protein 1 (BLIMP1) and its participation in the pathogenesis of B lymphomas. " 11/01/2009 - "PU.1 regulates positive regulatory domain I-binding factor 1/Blimp-1 transcription in lymphoma cells." 07/01/2010 - "B cells become antibody-secreting cells via plasmacytic differentiation, a process regulated by several transcription factors, including activator protein-1, B-cell CLL/lymphoma 6 (BCL-6), and B lymphocyte-induced maturation protein 1 (Blimp-1). " 07/01/2007 - "PRDM1 protein expression was recently demonstrated in a subset of diffuse large B-cell lymphoma (DLBCL) with aggressive behavior, a type of lymphoma for which rituximab associated with chemotherapy (R-CHOP) is now widely indicated. "

Related Drugs and Biologics

1.	Interleukin-10 (Interleukin 10)
2.	Carrier Proteins (Binding Protein)
3.	Proteins (Proteins, Gene)
4.	Chemokine Receptors
5.	Transcription Factors (Transcription Factor)
6.	Programmed Cell Death 1 Receptor
7.	MicroRNAs (MicroRNA)
8.	Chemokines
9.	Transcription Factor AP-1 (Transcription Factor AP 1)
10.	Interleukin-9 (Interleukin 9)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)